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Lack of Evidence for Activation of the Hedgehog
Pathway in Psoriasis
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John J. Voorhees1, Andrzej A. Dlugosz1 and James T. Elder1,3
Recent reports have suggested that the hedgehog (Hh) pathway is activated in lesional psoriatic skin, and that
treatment with the Hh pathway antagonist cyclopamine may lead to rapid resolution of the disease. To assess
Hh pathway activity in psoriasis, we isolated RNA from lesional and uninvolved skin of 58 psoriatic patients, and
from 63 normal control subjects, and subjected these samples to global gene expression profiling on Affymetrix
HU133 Plus 2.0 gene arrays. We were especially interested in Hh target genes (PTCH1 and GLI1), whose
expression is elevated in response to Hh signaling. The microarray data demonstrated downregulation of
PTCH1 expression in uninvolved and lesional skin (1.1-fold and 2-fold, respectively; Po0.0001). Additionally GLI1
mRNA was downregulated in lesional skin (1.7 fold; Po0.05). No significant changes were observed between
lesional and uninvolved skin for the Hh ligands or Smoothened. Quantitative PCR confirmed these findings. In
situ hybridization for GLI1 and PTCH1 was positive in basal cell carcinoma tumor cells, but was negligible in
uninvolved or lesional psoriatic skin. The absence of elevated Hh target gene expression in lesional psoriatic
skin indicates that the Hh pathway is not activated in this disease, raising questions regarding the proposed use
of Hh antagonists as antipsoriatic agents.
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INTRODUCTION
Psoriasis is a common chronic inflammatory skin disease
characterized by complex alterations in epidermal growth,
differentiation, and multiple, immunological, and vascular
abnormalities. Psoriasis was historically considered to be a
primary disorder of keratinocytes, but over the past two
decades it has been firmly established that psoriasis is an
immune disorder mediated by activated T cells (Gudjonsson
et al., 2004; Liu et al., 2007). How activated T cells mediate
the altered differentiation and hyperproliferation of keratino-
cytes and other changes observed in psoriasis is still unknown
but is thought to involve a highly complex, yet incompletely
understood, interaction of multiple cytokines and growth
factors with multiple cellular effectors present within the
psoriatic lesion. Additionally, the intercellular signaling
pathways mediating these changes remain to be fully
elucidated, although reports have indicated involvement
of the signal transducer and activator of transcription 1
(Bowcock et al., 2001), signal transducer and activator of
transcription 3 (Sano et al., 2005), mitogen-activated protein
kinase (Johansen et al., 2005b), activator protein 1 (Johansen
et al., 2004), and the NF-kB pathways (Lizzul et al., 2005;
Johansen et al., 2005a).
Recent reports have suggested that the hedgehog (Hh)
pathway is activated in lesional psoriatic skin (Kuenzli et al.,
2004; Tas and Avci, 2004; Endo et al., 2006; Meth and
Weinberg, 2006), and that pharmacological inhibition of this
pathway using cyclopamine may lead to rapid resolution of
the disease (Kuenzli et al., 2004; Tas and Avci, 2004; Meth
and Weinberg, 2006). The Hh signaling pathway is one of the
major signaling pathways involved in embryonic develop-
ment (Ingham and Placzek, 2006). During physiologic Hh
signaling, Hh proteins bind to the cell surface receptor
Patched (PTCH1), thereby releasing Smoothened (SMO) from
PTCH-mediated inhibition. SMO activation then triggers a
series of intracellular events, culminating in alterations in
gene expression mediated by the Gli family of transcription
factors (GLI1, GLI2, and GLI3; Ruiz i Altaba et al., 2007;
Figure 1). The transcripts for PTCH1 and GLI1 are reliable
markers for both physiologic and pathologic Hh signaling
activity as they are consistently induced when the Hh
pathway is activated (McMahon et al., 2003; Hutchin et al.,
2005). This pathway has been shown to be a crucial regulator
of hair follicle growth and sebaceous gland biology (Allen
et al., 2003; Niemann et al., 2003). On the other hand,
sustained activation of the Hh pathway appears to be the
driving force for basal cell carcinoma (BCC) development
(Daya-Grosjean and Couve-Privat, 2005).
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The involvement of the Hh pathway in psoriasis was first
suggested by the marked and rapid improvement observed in
a clinical trial, in which 31 individual psoriatic lesions in
seven patients, all with an established diagnosis of plaque or
guttate psoriasis, were treated with topical cyclopamine (Tas
and Avci, 2004). Furthermore, the authors asserted that
topical cyclopamine was more effective than the potent
topical steroid clobetasol-17 propionate, a typical first-line
therapy (Tas and Avci, 2004). Cyclopamine is a steroid
alkaloid that acts as an inhibitor of the Hh pathway by
binding directly to SMO and thus blocking activation of the
pathway. Cyclopamine is a potent teratogen that can lead to
severe fetal malformations including cyclopia (holoprosen-
cephaly; Belloni et al., 1996; Roessler et al., 1996). With
application of cyclopamine to the lesional skin marked
improvement was seen within 24 hours with near complete
clinical and histological clearance observed in 96 hours (Tas
and Avci, 2004). In another recent study it was demonstrated
by immunohistochemistry that GLI1 was overexpressed in
lesional skin whereas no expression was detected in either
uninvolved or control skin (Endo et al., 2006). Taken
together, these data suggested that Hh pathway activation is
proximal to other events in the pathogenesis of psoriasis and
that therapeutic manipulation of this pathway may lead to
rapid and possibly sustained improvement of psoriasis.
Despite these data, detailed evaluation of this pathway,
and its activation status, in psoriasis has been lacking.
We have collected large datasets on gene expression in
psoriasis to evaluate and dissect the pathogenic basis of this
enigmatic disease. Here, we investigate the principal
components of the Hh pathway in lesional, uninvolved,
and normal skin and expression of its downstream signature
target genes.
RESULTS
Microarray data
Several of the genes involved in the Hh Pathway showed
modest changes in expression among control, uninvolved,
and lesional skin (Figure 2), but in no case did we detect
evidence for activation of Hh signaling activity in psoriasis.
Expression of the PTCH1 gene was only slightly down-
regulated in uninvolved psoriatic skin (89% of control,
Po0.0001) with more pronounced downregulation in
lesional skin (51% of uninvolved, Po0.0001; Table 1),
compared to control skin. No changes were observed in the
expression levels of the PTCH2 gene. Both GLI1 and GLI2
were significantly downregulated in lesional psoriatic skin
(60 and 68% of uninvolved, Po0.05 and Po0.0001,
respectively; Table 1). Cyclin D1 (CCND1) was significantly
downregulated compared to uninvolved (2.2-fold,
Po0.0001) in lesional psoriatic skin whereas CCND2 was
upregulated (1.5-fold, Po0.0001), consistent with previously
published data (Belso et al., 2008). Additionally, CDC2 and
CCNB1 were also upregulated relative to uninvolved skin
(1.5-fold, 3.3-fold, and 5.6-fold, respectively; Po0.0001).
The Sonic hedgehog (SHH) and the Indian hedgehog (IHH)
gene expressions were minimally upregulated in uninvolved
psoriatic skin relative to control (1.06- and 1.05-fold,
Po0.05) whereas no change was observed for the desert
hedgehog (DHH) gene. No significant changes were ob-
served between lesional and uninvolved skin for the Hh
ligands or SMO (Table 1). Molecular network mapping
performed by ingenuity pathway analysis demonstrated
complete lack of activation of the Sonic hedgehog pathway
(data not shown).
Real-time quantitative PCR data
For confirmation of the microarray data, quantitative (QT)
real-time PCR was performed on RNA isolated from 10
control skin biopsies, 10 paired uninvolved and lesional
psoriatic skin biopsies, and 12 BCC samples, which served as
positive controls for Hh pathway activation. The expression
of the principal Hh pathway factors, GLI1 and PTCH1, were
significantly lower in lesional psoriatic skin than in BCC
(Po0.001; Figure 3). Furthermore, expression of these two
genes was lower in lesional skin compared to uninvolved
skin (P¼ 0.10 (GLI1), Po0.05 (PTCH1)). Expression of
PTCH2 and HHIP were significantly lower in lesional,
uninvolved, and control skin compared to BCC (Po0.01;
not shown), whereas the expression of keratin 1b and
CCND1 was decreased in both lesional skin and BCCs
compared to normal and uninvolved skin (Po0.001,
Po0.01, respectively; data not shown). CCND2 and myc
myelocytomatosis viral related oncogene (neuroblastoma
derived) expression levels were significantly lower in BCC
Hh
PTCH SMO
HHIP
GLI
GLI
HH Target genes:
PTCH, GLI1, etc.
HH
Figure 1. Highly simplified diagram illustrating key components of the Hh
signaling pathway. Signaling activators are indicated in green, signaling
inhibitors in red. In the absence of Hh ligands (SHH, IHH, or DHH), PTCH
blocks the function of the key signaling effector, SMO. Hh ligands block the
inhibitory effects of PTCH, leading to derepression of SMO and activation of
intracellular signaling. HH pathway activation leads to reprogramming of
gene expression via the GLI family of transcription factors (GLI1, GLI2, and
GLI3). Hh target genes, in addition to PTCH and GLI1, include the Hh
inhibitor protein HHIP, cyclins CCND1 and CCND2, and PTCH2.
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compared to lesional, uninvolved, and control samples
(Po0.01) whereas no difference was observed for GLI2,
SMO or the ligands SHH, IHH, and DHH (data not shown).
In situ hybridization
In situ hybridization for GLI1 and PTCH1 was strongly
positive in BCC tumor cells, which served as positive
controls. In contrast, negligible expression of GLI1 and
PTCH1 was detected in uninvolved or lesional psoriatic skin,
whereas staining for the control transcript, HPRT1, was
positive for all samples analyzed (Figure 4).
DISCUSSION
Psoriasis is characterized by marked hyperproliferation of
keratinocytes and influx of T cells with activated CD4þ T
cells predominating in the upper dermis and CD8þ T cells
in the epidermis. The pathogenesis is highly complex
with involvement and participation of multiple cell types
(Bowcock and Krueger, 2005). However, despite the inherent
complexity of the psoriatic process is has been shown to be
critically dependent on T-cell activation, as medications
inhibiting T-cell function can lead to remission of the disease
(Liu et al., 2007).
The Hh pathway is one of the main signaling pathways in
the developing embryo (Ingham and Placzek, 2006) and has
been shown to be crucial for the regulation and development
of hair follicles and sebaceous glands, and maintenance of
stem-cell populations in the skin (Levy et al., 2005). Its role in
human diseases, such as developmental disorders and cancer
(Xie et al., 1998; Mullor et al., 2002; Rubin and de Sauvage,
2006), has been firmly established. Activation of the pathway
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Figure 2. Heatmap of several Sonic hedgehog pathway genes. Several probes are present on the microarray for each gene. Different colors represent different
expression values on the log scale after quantile normalization, and batch and gender adjustment. Specifically, red indicates high expression values
whereas blue indicates low expression values on the log scale.
Table 1. Fold changes between uninvolved (U) and
control skin (N), and lesional psoriatic (P) vs
uninvolved
Genes
Fold changes
U vs N (P-value)
Fold changes
P vs U (P-value)
PTCH1 0.89 (Po0.0001) 0.51 (Po0.0001)
PTCH2 1.03 (NS) 1.00 (NS)
GLI1 1.03 (NS) 0.60 (Po0.05)
GLI2 0.92 (NS) 0.68 (Po0.0001)
HHIP 1.02 (NS) 1.00 (NS)
SHH 1.06 (Po0.05) 1.01 (NS)
DHH 1.00 (NS) 1.01 (NS)
IHH 1.05 (Po0.05) 1.06 (NS)
SMO 0.93 (NS) 1.06 (NS)
CCND1 0.96 (NS) 0.45 (Po0.0001)
CCND2 0.92 (NS) 1.47 (Po0.0001)
CDC2 1.09 (NS) 3.33 (Po0.0001)
CCNB1 1.07 (NS) 5.57 (Po0.0001)
NS, not significant.
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in keratinocytes has been shown to induce hyperproliferation
and resistance to exhaustion of replicative growth capacity
(Fan and Khavari, 1999). Additionally, the Hh pathway has
also been implicated in modulation of immune function of
peripheral CD4þ T-cells in a pro-inflammatory manner
(Lowrey et al., 2002; Stewart et al., 2002; Chan et al., 2006),
suggesting that the involvement of this pathway in psoriasis
pathogenesis might be plausible.
In this study, which is the largest and most detailed, yet on
the function and activity of this pathway in psoriasis we failed
to find any evidence of activation of the Hh pathway.
Importantly, no expression of GLI1 or PTCH1, the established
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Figure 3. QRT-PCR results for GLI1, PTCH1, and SMO are shown. Error bars indicate standard error of the mean (SEM; BCC, N¼ 12; control, N¼ 10;
uninvolved, N¼ 10; lesional, N¼ 10). Expression was significantly higher in basal cell carcinoma samples for GLI1 and PTCH1 genes (Po0.001), but was not
significant for SMO. Lesional skin had significantly lower expression of PTCH1 compared to uninvolved and control (Po0.05). GLI1 showed a trend for being
lower in lesional skin (P¼0.10) whereas no significant changes were seen for SMO.
GLI1
BCC
Uninvolved
Sense
Probe
Psoriasis
PTCH1 HPRT1
Figure 4. In situ hybridization reveals upregulation of Hh target genes, GLI1, and PTCH1 in BCC, but not psoriasis. Expression of the housekeeping transcript
HPRT1 confirmed RNA integrity in all samples. Staining with sense probe was done on BCC samples. Asterisks indicate regions of epithelium (**) and
basal cell carcinoma (*) (bar¼ 50mm).
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target genes of this pathway, could be observed in either the
inflammatory infiltrate or in the hyperproliferative epidermis.
In contrast to the expected upregulation of this pathway, our
results suggest that the activity of this pathway is in fact
slightly suppressed in lesional psoriatic skin. However, if the
Hh pathway is suppressed in lesional psoriatic skin, how can
the clinical efficacy of topical applied cyclopamine (Tas and
Avci, 2004) be explained? Cyclopamine is a steroidal
alkaloid derived from the false hellebore, or corn lily
(Veratrum californicum; reviewed in Kuenzli et al., 2004;
McFerren, 2006). It is a potent teratogen that on ingestion can
lead to severe fetal malformations including cyclopia and
holoprosencephaly (Cooper et al., 1998; Incardona et al.,
2000). It has been demonstrated that cyclopamine inhibits
Hh pathway activation by binding directly to SMO and this
inhibition is the underlying mechanisms whereby this
compound mediates its teratogenic effect (Chen et al.,
2002) as well as its inhibitory effect on BCCs (Taipale
et al., 2000). Whether the molecular effects of cyclopamine
on BCCs and psoriatic lesions share a common mechanism is
not known. Supporting such a common mechanism is a
recently published study where evidence of increased Hh
pathway activation in lesional psoriatic skin was provided
using immunohistochemistry to show upregulation of GLI1
expression in lesional psoriatic skin (Endo et al., 2006).
However, the staining was weak and only found diffusely in
the upper spinous layer, and Hh pathway activation was not
confirmed using other markers (Endo et al., 2006). As
immunohistochemistry is prone to a variety of artifacts, we
believe that it cannot be considered a reliable marker for Hh
pathway activity unless accompanied by other supportive
data. We could not find evidence for increased activity of the
Hh pathway in psoriasis, as determined by gene microarray
analysis, molecular pathway analyses, QT-PCR, and in situ
hybridization. Thus, our data indicate that the effect of this
compound, if truly effective in psoriasis, is likely to be
mediated through some other mechanism than blockade of
Hh signaling.
In conclusion, we could not confirm previously published
studies on the activation of the Hh pathway in lesional
psoriasis; in fact our results indicate that this pathway may be
modestly suppressed. Given the potential for harmful effects
of Hh antagonists, and the lack of evidence for Hh pathway
activation in psoriasis, our study raises questions regarding
the proposed use of these compounds as antipsoriatic agents.
MATERIALS AND METHODS
Biopsies, reagent, and gene chips
A total of 58 patients with chronic plaque psoriasis and 63 controls
were included in the study. The study was conducted according to
the Declaration of Helsinki Principles and was approved by the
University of Michigan Institutional Review Board and all patients
signed an informed consent before inclusion into the study. The
patients had not received any topical or systemic treatment for 2
weeks before the study. After local anesthesia with 1% lidocaine HCl
and 1:100,000 epinephrine (Hospira Inc. Lake Forest, IL), two 6mm
punch biopsies were obtained from each study subject. From
patients, one biopsy was obtained from lesional skin and the other
from uninvolved skin, taken at least 10 cm away from any active
plaque. The nonlesional biopsies were taken from the buttocks or
upper thighs of patients and controls. BCC samples were obtained
from Mohs micrographic surgery. The biopsies were snap frozen in
liquid nitrogen and stored at 80 1C. At processing the biopsy
samples were homogenized while still frozen and total RNA
extraction was performed using the RNeasy kit protocol (Qiagen,
Chatsworth, CA). RNA quantity and quality was measured on the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
RNA stabilization, isolation, and microarray sample labeling were
performed using standard methods for reverse transcription and one
round of in vitro transcription on 5 mg of total RNA. Samples were
run on HU133 Plus 2.0 and processed per the manufacturer’s
protocol (Affymetrix, Foster City, CA). The raw data from the
microarrays were processed using the Robust Multichip Average
method (Irizarry et al., 2003) and then normalized to account for
gender and batch effects. Specifically, we used a linear model to
estimate gender and batch effect and then subtracted them from the
raw expression data to get the normalized data.
In situ hybridization
In situ hybridization was performed using 5mm sections cut from NBF-
fixed, paraffin-embedded tissue as previously described (Grachtchouk
et al., 2003). Plasmid DNA, containing full-length cDNA, to make
riboprobe against human HPRT1 was purchased from Invitrogen
(clone ID 3163726) (Invitrogen, Carlsbad, CA). BglII or EcoRI
digestions followed by in vitro transcription using Sp6 or T7 promoters
were used to generate sense or senti-sense probes, respectively.
Real-time PCR
Quantitative (QT) real-time PCR was performed on paired lesional
and uninvolved samples from 10 psoriatic patients, 10 normal
controls, and 11 BCC samples. The RNA used was from the same
samples used for the gene microarrays. Primers for the genes, GLI1,
GLI2, PTCH1, PTCH2, SMO, CCND1, CCND2, IHH, SHH, DHH,
HHIP, RPLPO were obtained from Superarray Biosciences (Frederick,
MD). Results were normalized to the expression of the housekeeping
gene; Ribosomal protein, large, P0. The reverse transcription reaction
was performed on 0.5mg of RNA template and cDNAwas synthesized
using anchored-oligo(dT)18 primers as instructed by the manufacturer
(Roche Diagnostics, Mannheim, Germany). QT real-time PCR was
carried out on the LightCycler 2.0 system (Roche Diagnostics).
LightCycler FastStart DNA MasterPLUS SYBR Green I was used for all
PCR reactions as instructed by the manufacturer (Roche Diagnostics).
The reaction profile consisted of an initial denaturation at 95 1C for
15minutes followed by 40 cycles of PCR at 95 1C for 10 seconds
(denaturation), 58 1C for 10 seconds (annealing), and 72 1C for
10 seconds (extension). The fluorescence emitted was captured at
the end of the extension step of each cycle at 530nm.
Statistical analysis
Student’s T-test was used to analyze differences among the three
groups. Bonferroni correction was used and P-values were generated
from the microarray data. Paired T-test was used when uninvolved
and lesional psoriatic datasets were compared. The Sonic hedgehog
pathway network of genes and network analysis of microarray data
was performed using ingenuity pathway analysis (Ingenuity Systems:
www.analysis.ingenuity.com).
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